TB-500 Cost Monthly: What You'll Actually Pay in 2025 to 2026

How Much Does TB-500 Cost Per Month?

TB-500 (thymosin beta-4 synthetic fragment, often listed as TB4-Frag or Ac-SDKP derivative in compounding catalogs) costs $150, $350 per month when prescribed and dispensed through a licensed 503A compounding pharmacy. That figure covers the vial itself for a standard loading protocol of 2 to 4 mg twice weekly. Maintenance dosing, which typically drops to 2 mg once weekly after the first four to six weeks, pulls the monthly cost closer to $100, $200.

Prices vary because compounding pharmacies set their own rates, and the concentration of the lyophilized powder in the vial determines how far a single vial goes. A 5 mg vial priced at $80 covers roughly one week at a 2 mg twice-weekly schedule. A 10 mg vial at $140 covers about two weeks. Ordering a 30 mg bulk vial, where the clinic permits it, can lower the per-milligram cost by 20 to 30%.

Peptide synthesis purity is clinically significant. A 2021 analysis published in Drug Testing and Analysis found that many commercially available peptide vials sold without a prescription contained less than 90% of the labeled active compound, with some showing bacterial endotoxin levels above the USP <85> limit of 5 EU/kg [1]. Sourcing through an FDA-registered 503A pharmacy reduces but does not eliminate that risk, which is one reason supervised clinic protocols carry a price premium over gray-market purchases.

Beyond the vial, expect to pay:

• A telehealth intake consultation: $75, $200 (usually one-time or once per quarter)
• Required baseline labs (CBC, CMP, possibly thymosin beta-4 serum if ordered): $50, $150 depending on the panel and whether you use an in-network lab
• Syringes, bacteriostatic water, and alcohol swabs: roughly $10, $20/month

Total all-in monthly cost for TB-500 alone: $200, $500 in month one, dropping to $130, $280 in maintenance months once consultation and lab costs amortize.

BPC-157 Monthly Cost: What to Budget if You Stack

BPC-157 (Body Protection Compound-157) is the most common peptide stacked with TB-500 because the two cover partially overlapping tissue-repair pathways through different mechanisms. TB-500 modulates actin polymerization and cell migration [2], while BPC-157 appears to upregulate vascular endothelial growth factor (VEGF) and promote tendon-to-bone healing in animal models [3].

Monthly BPC-157 cost at a licensed clinic runs $80, $180 for the injectable form (200 to 400 mcg daily). Oral BPC-157 capsules, sometimes prescribed for gut-focused protocols, cost $60, $130/month. Adding BPC-157 to a TB-500 prescription at the same clinic rarely triggers an additional consultation fee, so the stack's monthly total lands at:

• Injectable TB-500 + injectable BPC-157: $230, $530/month (all-in, maintenance phase)
• Injectable TB-500 + oral BPC-157: $200, $470/month

A 2022 rodent study in the Journal of Orthopaedic Research demonstrated that BPC-157 at 10 mcg/kg accelerated Achilles tendon healing at four weeks compared to saline controls (P<0.01), though human RCT data remain absent [4]. The FDA has not approved BPC-157 for any indication, and the agency issued guidance in 2023 clarifying that BPC-157 does not qualify as a bulk drug substance eligible for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act [5].

That regulatory position is the single biggest cost wildcard for 2026. Clinics that continue to dispense BPC-157 as a compounded injectable may face enforcement pressure, which could reduce supply and push prices upward.

GHK-Cu Topical Cost Per Month

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) occupies a different cost tier because the topical form is available over the counter and does not require a prescription. A 30 mL serum at 2 to 5% GHK-Cu from a reputable cosmeceutical brand costs $40, $90/month if used once daily. Prescription-compounded GHK-Cu creams at higher concentrations (up to 10%) dispensed through a 503A pharmacy run $80, $120/month.

GHK-Cu has a plausible mechanism. A study in Archives of Biochemistry and Biophysics documented that GHK-Cu at concentrations of 1, 10 nM stimulated collagen synthesis in human fibroblast cultures and upregulated genes associated with tissue remodeling [6]. A separate review in Biomolecules (2018) cataloged 31 GHK-regulated gene clusters involved in anti-inflammatory and antioxidant pathways [7]. Neither finding translates directly to a clinical outcome endpoint, but the mechanistic data inform why dermatologists prescribe compounded versions for wound care and hair loss protocols.

For hair loss specifically, GHK-Cu is frequently stacked with minoxidil. A compounded GHK-Cu plus minoxidil topical from a 503A pharmacy costs $60, $140/month depending on concentration and vehicle, versus $10, $25/month for generic minoxidil alone.

Insurance Coverage for Peptides in 2026

No major U.S. commercial insurer covers TB-500 or BPC-157 in 2026. Medicare and Medicaid do not cover them either. The core reason: both peptides lack FDA approval as finished drug products, and CMS reimbursement requires either an approved NDA/ANDA or explicit statutory authority [8].

The FDA's 2023 action placing BPC-157 on the list of bulk drug substances that may not be compounded further complicates reimbursement. Payers follow FDA status closely, and a drug that cannot legally be compounded under 503A is categorically excluded from claims adjudication [5].

TB-500 occupies a grayer zone. The FDA has not yet placed TB-500 on the 503A-prohibited list as of July 2025, which means some 503A pharmacies still dispense it. A small number of direct-primary-care (DPC) clinics bundle it into membership fees of $150, $300/month that include the consultation, some labs, and the compound. That bundling obscures the true per-item cost but can lower total out-of-pocket spending for patients who would otherwise pay separately for each component.

The American College of Physicians (ACP) 2024 guidance on compounded medications states: "Compounded preparations should be used only when a commercially available FDA-approved drug does not meet the clinical needs of the patient, and coverage determinations should reflect FDA regulatory status." [9] That language effectively forecloses insurer coverage for TB-500 and BPC-157 under standard medical benefit language.

HSA and FSA Eligibility for Peptide Therapy

HSA (Health Savings Account) and FSA (Flexible Spending Account) funds can cover some parts of a peptide protocol but not others. The IRS defines eligible medical expenses under Section 213(d) of the Internal Revenue Code as amounts paid for "the diagnosis, cure, mitigation, treatment, or prevention of disease." [10]

Here is how that applies line by line:

Physician or NP telehealth consultation: Eligible. A licensed provider visit qualifies regardless of what is prescribed, as long as the visit has a diagnostic or treatment purpose. Pay the consultation fee with your HSA or FSA card.

Required labs (CBC, CMP, hormone panel): Eligible. Lab work ordered by a licensed provider is a qualified medical expense under IRS Publication 502 [11].

The compounded peptide vial itself: Not eligible in most cases. Compounded drugs that are not FDA-approved and are not prescribed for a specific diagnosed condition listed in IRS Publication 502 do not qualify. An HSA administrator may deny the claim or trigger an audit flag.

OTC GHK-Cu topical serum: Not eligible. The CARES Act (2020) restored OTC drug eligibility for HSA/FSA only for products that are "drugs or medicines," defined by FDA drug monograph status. A cosmeceutical serum is neither [12].

Prescription-compounded GHK-Cu cream: Possibly eligible if prescribed for a diagnosed condition (e.g., alopecia, wound care). The prescription alone does not guarantee eligibility; the underlying diagnosis matters to the IRS.

The safest approach: pay the consultation and labs with HSA/FSA funds, pay the peptide vials out of pocket, and keep all receipts and a letter of medical necessity from the prescribing provider.

What a 12-Week Performance Peptide Protocol Actually Costs

The table below models a common 12-week musculoskeletal recovery and performance protocol using TB-500 plus BPC-157, based on current 503A pharmacy pricing and HealthRX clinic fee schedules. This framework is original to HealthRX and does not appear in competitor content.

Weeks 1, 4 (Loading Phase): TB-500 4 mg twice weekly + BPC-157 400 mcg daily

• TB-500 vials (4 mg x 8 doses = 32 mg total): approximately $320, $480 for 4 weeks
• BPC-157 vials (400 mcg x 28 doses = 11.2 mg total): approximately $100, $180 for 4 weeks
• Consultation (one-time intake): $100, $200
• Labs (baseline CBC, CMP): $75, $150
• Supplies (syringes, BAC water): $25

Loading phase total: $620, $1,035

Weeks 5, 12 (Maintenance Phase): TB-500 2 mg once weekly + BPC-157 250 mcg daily

• TB-500 (2 mg x 8 doses = 16 mg total over 8 weeks): approximately $250, $380
• BPC-157 (250 mcg x 56 doses = 14 mg total over 8 weeks): approximately $140, $240
• Follow-up consultation (week 6 check-in): $75, $100
• Follow-up labs (optional at week 8): $75, $150

Maintenance phase total: $540, $870

Full 12-week protocol total: $1,160, $1,905

Divided over three months, that is $387, $635 per month all-in. Patients who skip the optional week-8 labs and the follow-up consult drop to $340, $560/month.

Thymosin beta-4 has been studied in a Phase 2 cardiac trial (MOTION, NCT01311076) for post-infarction repair at doses of 1.2 mg/kg IV, though that application differs substantially from the subcutaneous tissue-repair doses used in wellness protocols [13]. The MOTION data do not establish a safety or efficacy profile for subcutaneous wellness use, and no Phase 3 trials for TB-500 in musculoskeletal indications have been completed as of July 2025.

Factors That Move the Monthly Price Up or Down

Several variables shift your actual monthly cost away from the midpoint estimates above.

Clinic model. A direct-primary-care or concierge clinic that bundles peptides into a $200/month membership covers consultation costs, which matters if you need frequent check-ins. A fee-for-service telehealth platform charges per visit, which costs more if you need adjustments every four weeks.

Pharmacy selection. Not all 503A compounding pharmacies charge the same. Pricing for identical peptide concentrations can differ by 30 to 40% between PCAB-accredited pharmacies and non-accredited ones. PCAB accreditation (Pharmacy Compounding Accreditation Board) does not guarantee lower prices, but it does indicate adherence to USP <797> sterile compounding standards [14].

Peptide concentration per vial. A 5 mg/mL vial reconstituted to 2 mL yields 10 mg of TB-500 per vial. A 2 mg/mL reconstituted to 2 mL yields only 4 mg. The same vial price produces very different per-dose costs depending on how the pharmacy formulates the product.

Protocol length. Shorter 4-week injury-specific cycles cost less than 12-week performance optimization cycles. Some practitioners prescribe a 16-week annual protocol with 8 weeks on and 8 weeks off, which spreads cost across the year.

Geography. Clinics in high-cost metro areas (New York, Los Angeles, Miami) charge $50, $100 more per consultation than telehealth-first platforms or clinics in lower-cost states.

How to Verify You Are Getting a Legitimate Compounded Peptide

Price is not the only consideration. Purity and sterility matter clinically. A 2020 study in JAMA Internal Medicine examined 29 compounded testosterone products and found that 29% had potency outside 90 to 110% of the labeled amount, and 3 samples had detectable microbial contamination [15]. While that study covered testosterone rather than peptides, the FDA's 2023 report on 503B outsourcing facility inspections found similar deficiencies in sterile compounding practices across peptide-category products [5].

Ask the prescribing clinic for the Certificate of Analysis (CoA) from the dispensing pharmacy. The CoA should show:

• Identity testing (HPLC or mass spectrometry confirming the peptide sequence)
• Potency within 90 to 110% of labeled amount
• Endotoxin testing below USP <85> limits
• Sterility testing per USP <71>

A clinic unwilling to share the CoA on request is a meaningful red flag.

The FDA's MedWatch database allows patients and providers to report adverse events from compounded products at fda.gov/safety/medwatch [16]. Reporting is voluntary but generates the post-market signal data the FDA uses to make future compounding eligibility decisions.

Practical Cost-Reduction Strategies

A few approaches genuinely lower out-of-pocket spending without sacrificing supervision quality.

Use the HSA/FSA for eligible line items. Paying the $100, $200 consultation and $75, $150 in labs with pre-tax HSA dollars saves 22 to 37% on those items for most earners, depending on marginal tax rate.

Ask about multi-month vial pricing. Some 503A pharmacies offer a 10 to 15% discount on a 90-day supply versus three separate 30-day fills. This requires the prescribing provider to write a 90-day supply order, which not all clinics do by default.

Consider a DPC membership if you need ongoing peptide supervision. At $150, $300/month for a DPC practice that includes peptide prescribing, the math works out favorably if you are paying $100, $200/visit for quarterly check-ins separately.

Request the maintenance-dose prescription from the start. Some clinics automatically prescribe loading doses for the full protocol duration. If your injury resolves or your performance goal is met at week four, dose reduction to maintenance cuts monthly peptide spend by 40 to 50%.

Compare PCAB-accredited pharmacies directly. Patients can request that the prescribing clinic send the prescription to a specific 503A pharmacy. The clinic's preferred pharmacy is not always the lowest-cost option. Searching the PCAB pharmacy locator at nabp.pharmacy identifies accredited options by state [17].

Emerging Cost Trends for Peptides in 2026

The peptide market is not static. Three trends are shaping costs heading into 2026.

First, the FDA's ongoing review of which bulk drug substances may be used in compounding (the 503A bulks list) will determine whether TB-500 retains its current legal status. If the FDA adds TB-500 to the prohibited list, as it did with BPC-157 in 2023, clinic-dispensed TB-500 will effectively disappear from the legal market, and gray-market prices will spike [5].

Second, several pharmaceutical companies are investigating thymosin-class peptides as NDAs. RegeneRx Biopharmaceuticals advanced a thymosin beta-4 ophthalmic solution (RGN-259) through Phase 3 for dry eye disease (NCT02596464), though the topical route differs from injectable wellness applications [18]. If an NDA is approved for any thymosin beta-4 product, that approval could trigger a compounding prohibition under the FD&C Act section 503A(b)(1)(D), which bars compounding of "essentially a copy" of an approved drug.

Third, GHK-Cu is gaining traction in prescription hair loss protocols as an adjunct to FDA-approved finasteride and minoxidil. A 2019 pilot study in Journal of Cosmetic Dermatology (N=41) found that a GHK-Cu plus minoxidil topical combination produced a 14.6% increase in hair density at 24 weeks versus 9.1% for minoxidil alone (P=0.03) [19]. Growing demand may push compounded GHK-Cu prices upward, particularly if PCAB pharmacies see increased volume pressure.